HOME ·

HENGRUI PHARMA

HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-20
HENGRUI PHARMA(01276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.47 billion, YoY increase of 0.34%
Tags：
HENGRUI PHARMA01276.HKprofit
2026-08-20
HENGRUI PHARMA (01276.HK): Proposes Adoption of 2026 H-Share Scheme with Mandate Limit of Not More Than 1,000,000 H Shares
Tags：
HENGRUI PHARMA01276.HKShare Scheme
2026-08-19
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): Trastuzumab Rezetecan Approved for Third Indication, Becoming China's First Anti-HER2 Product Approved for Colorectal Cancer
Tags：
HENGRUI PHARMA01276.HKIndications approved
2026-08-06
HENGRUI PHARMA (01276.HK): Class 1 Innovative Drug Ivarmacitinib Sulfate Tablets Approved for Fifth Indication, Completing Full-Disease-Spectrum Coverage of Axial Spondyloarthritis
Tags：
HENGRUI PHARMA01276.HKbiopharmaceutical
2026-08-06
HENGRUI PHARMA(01276.HK): SHR‑A2009 for Injection Combined with Adebrelimab Obtains NMPA Clinical Trial Approval for Non‑Small‑Cell Lung Cancer
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-08-04
Metis TechBio-P (07666.HK): AiTEM AI Formulation Platform Partners with HENGRUI PHARMA to Accelerate Drug Formulation Development
Tags：
METIS TECHBIO-P07666.HKHENGRUI PHARMA01276.HKAiTEM
2026-08-03
HENGRUI PHARMA (01276.HK): Receives CRL from FDA for Camrelizumab Liver Cancer Indication, Related to cGMP Inspection Findings at Apatinib Manufacturing Site
Tags：
HENGRUI PHARMA01276.HKPharmaceutical Updates
2026-07-10
HENGRUI PHARMA (01276.HK): SHR-4685 Injection Obtains Clinical Trial Approval for Advanced Solid Tumours
Tags：
HENGRUI PHARMA01276.HKClinical Trial Application
2026-07-07
Hengrui Pharma (01276.HK): Enters Global Strategic Collaboration with Bristol Myers Squibb, Total Transaction Value Up to ~US$15.2 Billion
Tags：
HENGRUI PHARMA01276.HKStrategic Collaboration
2026-05-12
HENGRUI PHARMA (01276.HK): Five Innovative Drugs Obtain Clinical Trial Approvals, Targeting KRAS G12D and Other Indications
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): HRS-3005 Tablets Granted Clinical Trial Approval for B-Cell Malignancies
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 2.28 billion, YoY increase of 21.78%
Tags：
HENGRUI PHARMA01276.HKfinancials
2026-04-23
HENGRUI PHARMA(01276.HK): Receives Clinical Trial Approval for SHR-1049 Injection, Targeting Advanced Solid Tumors
Tags：
HENGRUI PHARMA01276.HK
2026-01-26